Business Wire

ADVA launches world’s first optical transport solution with post-quantum cryptography

8.7.2021 10:00:00 EEST | Business Wire | Press release

Share

ADVA (FSE: ADV) today launched the industry’s first optical transport solution secured by post-quantum cryptography (PQC). The FSP 3000 ConnectGuard™ optical encryption solution now protects data against cyberattacks from quantum computers that could break today’s cryptographic algorithms. The quantum-safe security technology relies on a hybrid key exchange system, combining PQC algorithms with classical encryption methods. Built for crypto-agility, the solution is ready for software updates in the future, ensuring it delivers the most robust network protection now and for decades to come.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210708005050/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ADVA’s FSP 3000 ConnectGuard™ encryption solution now protects data against cyberattacks from quantum computers (Photo: Business Wire)

“Our market-first FSP 3000 quantum-safe ConnectGuard encryption technology answers the urgent threat posed by quantum computers and gives organizations a way to safeguard their networks before the danger materializes. Our customers’ data will be fully protected even from cybercriminals’ intent on harvesting information so that they can store it today and exploit it tomorrow,” said Christoph Glingener, CTO, ADVA. “We’re providing long-term security for data in motion. What’s more, our solution is ready to be upgraded later to comply with emerging specifications, including the NIST’s PQC standardization competition.”

As recommended by leading cybersecurity authorities, the PQC-protected ADVA FSP 3000 ConnectGuard encryption solution utilizes the traditional Diffie-Hellman protocol and combines it with a newly developed algorithm based on the quantum-safe McEliece cryptosystem. This enables it to produce encryption keys that even powerful quantum computers will be unable to crack. As well as delivering data integrity with quantum-safe Layer 1 AES-256 protection, the ADVA FSP 3000 ConnectGuard encryption solution ensures minimal impact on latency, throughput and performance. The technology is also easily deployable over long-haul and multi-operator links.

“Organizations everywhere have woken up to the security threat that quantum computing represents. With many experts anticipating powerful commercially available quantum computers in the next decade, it’s now widely understood that the danger is very real and the stakes are enormously high. That’s why we’ve invested so much time and energy into developing the world’s first transport solution ready for the challenges ahead,” commented Jörg-Peter Elbers, SVP, advanced technology, ADVA. “By integrating PQC security into our FSP 3000 ConnectGuard optical encryption solution, we’re empowering our customers to protect their networks today against tomorrow’s threats. Our solution is easily deployable and only requires end-point access. What’s more, it works over any distance and in any optical transport network.”

Watch this Tech Cam video for more information: https://youtu.be/4fs6zV5FnME.

Further details are also available in these slides: https://adva.li/pqc-slides.

A supporting solution brief can be downloaded here: https://adva.li/pqc-solution-brief.

About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

Published by:

ADVA Optical Networking SE, Munich, Germany

www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 14:00:00 EEST | Press release

Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction. GreensLedge Capital Markets advised the seller. About Clearlake Clearlake Capital is a leading global alternative a

Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 14:00:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrated statistical superiority over deucravacitinib for all key secondary endpoints, including PASI 90 response and Static Physician's Global Assessment (sPGA) 0 at week 16. Zasocitinib was generally well tolerated with a consistent safety and tolerability profile and no new safety signals identified. Perspectives on head-to-head zasocitinib study “In this head-to-head study, zasocitinib clearly demonstrated

L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 13:30:00 EEST | Press release

L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reliability, operational efficiency and sustainability performance. The partnership brings together LTTS’ expertise in forward looking technologies and extensive experience ac

Faire Marks Five Years of Growth Outside North America: Over 100,000 Retailers, 50,000 Brands, and More Than One in Four Brands Now Selling Across Borders11.6.2026 12:05:00 EEST | Press release

Five years after launching outside North America, Faire’s community of more than 100,000 retailers and 50,000 brands across 30+ countries in Europe, Australia, and New Zealand shows a retail sector that is innovating and thriving, well beyond the big cities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611115823/en/ Faire Celebrates 5 Years of Growth in Europe "It has been a phenomenal five years for Faire internationally, and the opportunity ahead has never been clearer,” said Olivier Buffon, VP and Head of International at Faire. “Europe represents a retail market comparable in scale to North America, and the challenges Faire was built to solve exist wherever independent retail exists. A global platform is more valuable for everyone, and we’re so proud to support businesses becoming more confident and more global in how they buy and sell.” A Retailer Network Spanning Tens of Thousands of Towns Independent retail is al

Stallergenes Greer Will Present New Evidence on Long-term Outcomes in Allergen Immunotherapy at EAACI 202611.6.2026 11:09:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, will present new clinical evidence and scientific advances in allergen immunotherapy (AIT) at the European Academy of Allergy and Clinical Immunology (EAACI) congress, taking place from June 12 to 15 in Istanbul, Turkey. The company will host a scientific symposium entitled “From Nobel Prize discovery to AIT clinical evidence: Shaping pathways to respiratory allergy remission.”Three leading international experts will explore how landmark breakthroughs in immunology have deepened our understanding of immune tolerance, presenting emerging data on remission and long-term outcomes in respiratory allergy. Together, these insights reinforce AIT’s disease-modifying potential and its growing role in personalised medicine. “EAACI 2026 is an exceptional forum for the global allergy community to exchange knowledge and advance the field. Stallergenes Greer is proud contribute to these conversations, bringing together world-leading experts in pur

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye